Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Synlogic Inc (SYBX)

Synlogic Inc (SYBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Synlogic Reports Third Quarter 2024 Financial Results

SYBX : 1.4000 (-6.50%)
Synlogic Flat on Q1 Numbers

Synlogic, Inc. (NASDAQ: SYBX) waned Tuesday, after reporting financial results for the first quarter ...

SYBX : 1.4000 (-6.50%)
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...

SYBX : 1.4000 (-6.50%)
DNA : 10.24 (-7.83%)
Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update

– Three clinical data readouts across three programs expected in H2 2022 – – PKU Phase 3 readiness activities underway for planned start in H1 2023 – – ...

SYBX : 1.4000 (-6.50%)
Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)

Expected data in H2 2022 brings Synlogic to three clinical readouts this year Third candidate in less than two years to enter the clinic; Reflects...

SYBX : 1.4000 (-6.50%)
Synlogic Announces Appointment of General Counsel and Corporate Secretary

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for...

SYBX : 1.4000 (-6.50%)
Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference

VANCOUVER, Wash., June 28, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for...

SYBX : 1.4000 (-6.50%)
Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference

BETHESDA, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic...

SYBX : 1.4000 (-6.50%)
Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update

- Clinical readouts anticipated for phenylketonuria (PKU), homocystinuria (HCU) and enteric hyperoxaluria programs in H2 2022 – - PKU program progressing...

SYBX : 1.4000 (-6.50%)
Synlogic Announces Data Presentations from Five Programs at the 2022 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for...

SYBX : 1.4000 (-6.50%)

Barchart Exclusives

This Penny Oil Stock Keeps Tearing Higher. Is It a Buy, Sell, or Hold for 2025?
Rallying 72% in the new year to date, can this penny oil stock sustain its momentum? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar